G. Cooper, M. Bynum, and E. Somers, Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases, Journal of Autoimmunity, vol.33, issue.3-4, pp.3-4197, 2009.
DOI : 10.1016/j.jaut.2009.09.008

L. Burkly, J. Michaelson, K. Hahm, A. Jakubowski, and T. Zheng, TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease, Cytokine, vol.40, issue.1, 2007.
DOI : 10.1016/j.cyto.2007.09.007

N. Wisniacki, L. Amaravadi, G. Galluppi, T. Zheng, R. Zhang et al., Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis, Clinical Therapeutics, vol.35, issue.8, pp.1137-1186, 2013.
DOI : 10.1016/j.clinthera.2013.06.008

A. Anti-tweak-in, Available from: http://clinicaltrials.gov/ct2, Lupus Nephritis Patients. Clinical Trials.gov, 2013.

N. Schwartz, T. Rubinstein, L. Burkly, C. Collins, I. Blanco et al., Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study, Arthritis Research & Therapy, vol.11, issue.5, pp.10-1186, 2009.
DOI : 10.1186/ar2816

A. El-shehaby, H. Darweesh, M. El-khatib, M. Momtaz, S. Marzouk et al., Correlations of Urinary Biomarkers, TNF-Like Weak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemoattractant Protein-1 (MCP-1), and IL-8 with Lupus Nephritis, Journal of Clinical Immunology, vol.85, issue.3, pp.31848-56, 2011.
DOI : 10.1159/000045663

S. Perper, B. Browning, L. Burkly, S. Weng, C. Gao et al., TWEAK Is a Novel Arthritogenic Mediator, The Journal of Immunology, vol.177, issue.4, pp.2610-2630, 2006.
DOI : 10.4049/jimmunol.177.4.2610

URL : http://www.jimmunol.org/content/jimmunol/177/4/2610.full.pdf

K. Kamata, S. Kamijo, A. Nakajima, A. Koyanagi, H. Kurosawa et al., Involvement of TNF-Like Weak Inducer of Apoptosis in the Pathogenesis of Collagen-Induced Arthritis, The Journal of Immunology, vol.177, issue.9, pp.6433-6442, 2006.
DOI : 10.4049/jimmunol.177.9.6433

M. Park, S. Chung, S. Jung, Y. Park, and S. Lee, Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti???TNF treatment in patients with rheumatoid arthritis, Scandinavian Journal of Rheumatology, vol.29, issue.3, pp.173-810, 1080.
DOI : 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U

K. Yanaba, A. Yoshizaki, E. Muroi, T. Hara, F. Ogawa et al., Elevated Circulating TWEAK Levels in Systemic Sclerosis: Association with Lower Frequency of Pulmonary Fibrosis, The Journal of Rheumatology, vol.36, issue.8, pp.1657-62, 2009.
DOI : 10.3899/jrheum.081310

B. Serafini, R. Magliozzi, B. Rosicarelli, R. Reynolds, T. Zheng et al., Expression of TWEAK and Its Receptor Fn14 in the Multiple Sclerosis Brain: Implications for Inflammatory Tissue Injury, Journal of Neuropathology & Experimental Neurology, vol.67, issue.12, pp.1137-1185, 2008.
DOI : 10.1002/glia.20208

A. Van-kuijk, C. Wijbrandts, M. Vinkenoog, T. Zheng, K. Reedquist et al., TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.301-305, 2008.
DOI : 10.1136/ard.2008.090548

S. Desplat-jégo, S. Varriale, R. Creidy, R. Terra, D. Bernard et al., TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity, Journal of Neuroimmunology, vol.133, issue.1-2, pp.116-139, 2002.
DOI : 10.1016/S0165-5728(02)00368-5

S. Desplat-jégo, R. Creidy, S. Varriale, N. Allaire, Y. Luo et al., Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis, Clinical Immunology, vol.117, issue.1, pp.15-23, 2005.
DOI : 10.1016/j.clim.2005.06.005

M. Nakayama, N. Kayagaki, N. Yamaguchi, K. Okumura, and H. Yagita, Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity, J Exp Med, vol.192, issue.9, 2000.

M. Kaplan, D. Ray, R. Mo, R. Yung, and B. Richardson, TRAIL (Apo2 Ligand) and TWEAK (Apo3 Ligand) Mediate CD4+ T Cell Killing of Antigen-Presenting Macrophages, The Journal of Immunology, vol.164, issue.6, pp.2897-904, 2000.
DOI : 10.4049/jimmunol.164.6.2897

S. Desplat-jégo, L. Feuillet, R. Creidy, I. Malikova, R. Rance et al., TWEAK is expressed at the cell surface of monocytes during multiple sclerosis, Journal of Leukocyte Biology, vol.85, issue.1, pp.132-137, 2009.
DOI : 10.1189/jlb.0608347

A. Dharmapatni, M. Smith, T. Crotti, C. Holding, C. Vincent et al., TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis, Arthritis Research & Therapy, vol.13, issue.2, pp.51-61, 2011.
DOI : 10.1359/jbmr.090320

N. Schwartz, L. Su, L. Burkly, M. Mackay, C. Aranow et al., Urinary TWEAK and the activity of lupus nephritis, Journal of Autoimmunity, vol.27, issue.4, 2006.
DOI : 10.1016/j.jaut.2006.12.003

Z. Liu, Q. Zhou, X. Li, J. Yang, X. Ao et al., Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus, Cytokine, vol.53, issue.3, pp.295-300, 2011.
DOI : 10.1016/j.cyto.2010.11.012

M. Bielecki, K. Kowal, A. Lapinska, J. Chwiecko, J. Skowronski et al., Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis., Folia Histochemica et Cytobiologica, vol.47, issue.3, pp.465-474, 2009.
DOI : 10.2478/v10042-009-0103-2

J. Moreno, B. Muñoz-garcía, J. Martín-ventura, J. Madrigal-matute, J. Orbe et al., The CD163-expressing macrophages recognize and internalize TWEAK, Atherosclerosis, vol.207, issue.1, 2009.
DOI : 10.1016/j.atherosclerosis.2009.04.033

L. Bover, M. Cardó-vila, A. Kuniyasu, J. Sun, R. Rangel et al., A Previously Unrecognized Protein-Protein Interaction between TWEAK and CD163: Potential Biological Implications, The Journal of Immunology, vol.178, issue.12, pp.8183-94, 2007.
DOI : 10.4049/jimmunol.178.12.8183

URL : http://www.jimmunol.org/content/jimmunol/178/12/8183.full.pdf

A. Fick, I. Lang, V. Schäfer, A. Seher, J. Trebing et al., Studies of Binding of Tumor Necrosis Factor (TNF)-like Weak Inducer of Apoptosis (TWEAK) to Fibroblast Growth Factor Inducible 14 (Fn14), Journal of Biological Chemistry, vol.177, issue.1, pp.484-95, 2012.
DOI : 10.1074/jbc.M109.087635

O. Kowal-bielecka, M. Bielecki, S. Guiducci, B. Trzcinska-butkiewicz, M. Michalska-jakubus et al., High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis, Arthritis Research & Therapy, vol.15, issue.3, pp.69-79, 2013.
DOI : 10.1016/j.jcpa.2011.01.012

M. Yilmaz, J. Carrero, A. Ortiz, J. Martin-ventura, A. Sonmez et al., Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease, Clinical Journal of the American Society of Nephrology, vol.4, issue.11, pp.1716-1739, 2009.
DOI : 10.2215/CJN.02760409

E. Chorianopoulos, K. Jarr, H. Steen, E. Giannitsis, N. Frey et al., Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome, Atherosclerosis, vol.211, issue.1, pp.322-328, 2010.
DOI : 10.1016/j.atherosclerosis.2010.02.016

L. Xia, H. Shen, X. W. Lu, and J. , Increased serum TWEAK levels in Psoriatic arthritis: Relationship with disease activity and matrix metalloproteinase-3 serum levels, Cytokine, vol.53, issue.3, pp.289-91, 2011.
DOI : 10.1016/j.cyto.2010.12.003

K. Turmen, H. Tonbul, F. Erdur, A. Toker, Z. Biyik et al., Soluble TWEAK independently predicts atherosclerosis in renal transplant patients, BMC Nephrology, vol.182, issue.11, pp.144-154, 2013.
DOI : 10.4049/jimmunol.0801772

G. Llaurado, J. Gonzalez-clemente, E. Maymo-massip, D. Subias, J. Vendrell et al., Serum Levels of TWEAK and Scavenger Receptor CD163 in Type 1 Diabetes Mellitus: Relationship with Cardiovascular Risk Factors. A Case-Control Study, PLoS ONE, vol.7, issue.8, 2012.
DOI : 10.1371/journal.pone.0043919.t005

A. Lammens, M. Baehner, U. Kohnert, J. Niewoehner, L. Von-proff et al., Crystal Structure of Human TWEAK in Complex with the Fab Fragment of a Neutralizing Antibody Reveals Insights into Receptor Binding, PLoS ONE, vol.287, issue.5, 2013.
DOI : 10.1371/journal.pone.0062697.t003

D. Bertin, D. Stephan, M. Khrestchatisky, and S. Desplat-jégo, Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases? Front, Immunol, 2013.
DOI : 10.3389/fimmu.2013.00489

URL : http://journal.frontiersin.org/article/10.3389/fimmu.2013.00489/pdf